| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.2 |